Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Product revenue	$ 1,204	$ 2,539
Funded research and development revenue	0	13
Total revenue	1,204	2,552
Operating costs and expenses:
Cost of product revenue	578	939
Research and product development expenses:
Funded research and product development	0	25
Unfunded research and product development	373	385
Total research and product development expenses	373	410
Selling, general and administrative expenses	1,092	1,307
Operating loss	(839)	(104)
Gain on derivatives	0	44
Other income (expense), net	3	(2)
Loss before non-controlling interest	(836)	(62)
Plus: Net loss attributed to non-controlling interest	14	256
Net (loss) income attributed to MTI	(822)	194
Comprehensive (loss) income attributed to MTI	$ (822)	$ 194
Net (loss) earnings per share attributable to MTI (Basic and Diluted): (in dollars per share)	$ (0.16)	$ 0.04
Weighted average shares outstanding (Basic and Diluted) (in shares)	5,254,883	4,771,658